Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR/ ALK-negative Advanced NSCLC”

12 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 12 results

Not applicableUnknownNCT03764917
What this trial is testing

NGS Combined With RNAseq on Tumor Immune Escape in NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 100
Testing effectiveness (Phase 2)Looking for participantsNCT06749886
What this trial is testing

An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting

Who this might be right for
Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 22
Large-scale testing (Phase 3)Ended earlyNCT04427072
What this trial is testing

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 22
Testing effectiveness (Phase 2)Study completedNCT04677595
What this trial is testing

Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals 37
Testing effectiveness (Phase 2)Enrolling By InvitationNCT06260553
What this trial is testing

Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC

Who this might be right for
EGFR/ ALK-negative Advanced NSCLC
Fujian Cancer Hospital 40
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University 156
Testing effectiveness (Phase 2)UnknownNCT05675033
What this trial is testing

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Who this might be right for
Lung AdenocarcinomaStage IV Non-small Cell Lung CancerPD-1 Inhibitor+1 more
Fujian Cancer Hospital 50
Early research (Phase 1)Active Not RecruitingNCT03611738
What this trial is testing

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Who this might be right for
Non-small Cell Lung CancerLung CancerNon-small Cell Lung Cancer Metastatic+3 more
H. Lee Moffitt Cancer Center and Research Institute 21
Testing effectiveness (Phase 2)Study completedNCT03647488
What this trial is testing

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 18
Testing effectiveness (Phase 2)UnknownNCT03654027
What this trial is testing

Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC

Who this might be right for
Non-small Cell Lung Cancer
First Affiliated Hospital of Guangxi Medical University 84
Testing effectiveness (Phase 2)Ended earlyNCT04323436
What this trial is testing

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 31
Testing effectiveness (Phase 2)Looking for participantsNCT07330596
What this trial is testing

QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
Anhui Provincial Cancer Hospital 96